BDX
Status-Quo-PlayerBecton Dickinson
$155.43
+0.76%
as of 13 Apr
Power Core
BD's moat is the aggregate regulatory and clinical switching cost across its multi-category portfolio, which no single competitor can replicate or attack simultaneously.
Direction of Movement
Lateral Trajectory With Selective Upward Vectors
ROC 200
+14.2%
BDX
Becton Dickinson
$155.43
+0.76%
as of 13 Apr
DCF Fair Value: $1,225.93
Market data unavailable
Company Profile
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad portfolio of medical supplies, devices, laboratory equipment, and diagnostic products. It serves healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies, and the general public worldwide. Key segments include BD Medical, offering peripheral IV and advanced catheters, vascular access technologies, infusion therapy systems, prefillable drug delivery, and sharps disposal; BD Life Sciences, providing specimen collection, blood culturing, molecular testing, flow cytometry, and diagnostic reagents; and BD Interventional, featuring hernia repair, surgical infection prevention, peripheral intervention, urology, and critical care products. Following its spinoff, revenue derives primarily from BD Medical Essentials, Interventional, Connected Care, and Biopharma segments, with significant international operations. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company plays a vital role in advancing medical discovery, diagnostics, and care delivery across the healthcare sector.